US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
JP2003521930A
(ja)
|
2000-02-11 |
2003-07-22 |
マキシゲン・エイピーエス |
第VII因子または第VIIa因子様分子
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
CA2420892A1
(en)
|
2000-09-13 |
2002-03-21 |
Novo Nordisk A/S |
Human coagulation factor vii variants
|
AU8755001A
(en)
*
|
2000-09-13 |
2002-03-26 |
Novo Nordisk As |
Human coagulation factor vii variants
|
US7173000B2
(en)
|
2000-11-09 |
2007-02-06 |
The Scripps Research Institute |
Modified factor VIIa
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
CA2461003A1
(en)
*
|
2001-09-27 |
2003-04-03 |
Novo Nordisk Health Care Ag |
Human coagulation factor vii polypeptides
|
US7052868B2
(en)
|
2001-09-27 |
2006-05-30 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
AU2002336919A1
(en)
*
|
2001-11-02 |
2003-05-12 |
Novo Nordisk Health Care Ag |
Human coagulation factor vii polypeptides
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
JP2005515175A
(ja)
*
|
2001-11-09 |
2005-05-26 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第vii因子ポリペプチドおよびアルファ2−抗プラスミンポリペプチドを含む薬学的組成物
|
EP1446155A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk A/S |
Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und aprotinin-polypeptiden
|
EP1446153A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk Health Care AG |
Pharmazeutische zusammensetzung mit faktor-vii- polypeptiden und gewebeplasminogen-inhibitoren
|
JP2005510513A
(ja)
*
|
2001-11-09 |
2005-04-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドおよびtafiポリペプチドを含む薬学的組成物
|
US7291587B2
(en)
|
2001-11-09 |
2007-11-06 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
|
EP1446146A1
(de)
*
|
2001-11-09 |
2004-08-18 |
Novo Nordisk Health Care AG |
Pharmazeutische zusammensetzung mit faktor-vii-polypeptiden und pai-1 polypeptiden
|
JP2005510515A
(ja)
*
|
2001-11-09 |
2005-04-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Vii因子ポリペプチドおよびプロテインc阻害剤を含む薬学的組成物
|
US7078479B2
(en)
|
2001-11-09 |
2006-07-18 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
|
ATE428439T1
(de)
|
2001-12-21 |
2009-05-15 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzung aus faktor vii polypeptiden
|
DE60334983D1
(de)
|
2002-04-30 |
2010-12-30 |
Bayer Healthcare Llc |
Faktor vii oder faktor viia polypeptidvarianten
|
KR101212025B1
(ko)
|
2002-06-21 |
2013-01-09 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
|
WO2004000366A1
(en)
|
2002-06-21 |
2003-12-31 |
Novo Nordisk Health Care Ag |
Pegylated factor vii glycoforms
|
US6933136B2
(en)
|
2002-09-20 |
2005-08-23 |
Novo Nordisk A/S |
Method for making recombinant proteins
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
DE60330923D1
(de)
|
2002-09-25 |
2010-02-25 |
Novo Nordisk Healthcare Ag |
Menschliche Koagulationsfaktor VII Polypeptide
|
AU2004221758B2
(en)
|
2003-03-18 |
2010-07-22 |
Novo Nordisk Health Care Ag |
Method for the production of GLA-residue containing serine proteases
|
US7771996B2
(en)
|
2003-03-20 |
2010-08-10 |
Bayer Healthcare Llc |
FVII or FVIIa variants
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP2338333B1
(de)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
NZ544728A
(en)
|
2003-06-19 |
2009-04-30 |
Bayer Healthcare Llc |
Factor VII or VIIa Gla domain variants
|
EP1641487B1
(de)
*
|
2003-06-25 |
2012-02-29 |
Novo Nordisk Health Care AG |
Flüssige zusammensetzungen von factor vii polypeptiden
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
EP2392655A3
(de)
|
2003-09-09 |
2012-02-29 |
Novo Nordisk Health Care AG |
Gerinnungsfaktor VII Polypeptide
|
WO2005032581A2
(en)
|
2003-10-07 |
2005-04-14 |
Novo Nordisk Health Care Ag |
Hybrid molecules having factor vii/viia activity
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
ES2507091T3
(es)
|
2003-12-01 |
2014-10-14 |
Novo Nordisk Health Care Ag |
Nanofiltración de soluciones del factor VII para eliminar virus
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
EP2298287B1
(de)
|
2003-12-19 |
2018-04-11 |
Novo Nordisk Health Care AG |
Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
|
CN103215328B
(zh)
|
2004-01-21 |
2016-08-03 |
诺和诺德医疗保健公司 |
转谷氨酰胺酶介导的肽的接合
|
JP2007522805A
(ja)
*
|
2004-02-03 |
2007-08-16 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
新規化合物
|
EP1814573B1
(de)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
EP1831242B1
(de)
|
2004-12-23 |
2012-09-26 |
Novo Nordisk Health Care AG |
Reduktion des gehaltes an kontaminierenden proteinen in zusammensetzungen, die vitamin k-abhängige proteine von interesse umfassen
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
EP1871795A4
(de)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
JP5147692B2
(ja)
|
2005-07-13 |
2013-02-20 |
ノボ ノルディスク ヘルス ケア アーゲー |
治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
EP1924689B1
(de)
|
2005-09-01 |
2014-08-13 |
Novo Nordisk Health Care AG |
Reinigung von faktor-vii-polypeptiden mittels hydrophober interaktionschromatografie
|
US20090055942A1
(en)
|
2005-09-14 |
2009-02-26 |
Novo Nordisk Healthcare A/G |
Human Coagulation Factor VII Polypeptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
EP2059527B1
(de)
|
2006-09-01 |
2014-12-03 |
Novo Nordisk Health Care AG |
Modifizierte glykoproteine
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
US8637007B2
(en)
|
2006-12-15 |
2014-01-28 |
Baxter International Inc. |
Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
|
EP2144923B1
(de)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Behandlungsverfahren mit glycopegyliertem g-csf
|
CA2683443A1
(en)
|
2007-04-13 |
2008-10-23 |
Catalyst Biosciences, Inc. |
Modified factor vii polypeptides and uses thereof
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
DK2574676T3
(en)
|
2007-12-27 |
2017-10-09 |
Baxalta GmbH |
Methods of cell culture
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
TWI465247B
(zh)
|
2008-04-11 |
2014-12-21 |
Catalyst Biosciences Inc |
經修飾的因子vii多肽和其用途
|
CA2764872C
(en)
|
2009-06-09 |
2018-07-24 |
Prolong Pharmaceuticals, LLC |
Hemoglobin compositions
|
FR2947181B1
(fr)
*
|
2009-06-26 |
2012-05-04 |
Lfb Biotechnologies |
Composition de facteur vii
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CN104530182A
(zh)
|
2009-07-27 |
2015-04-22 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
CN102573920B
(zh)
|
2009-07-27 |
2015-01-14 |
利普森技术有限公司 |
非凝血蛋白的糖基多唾液酸化
|
RU2595442C2
(ru)
|
2009-07-27 |
2016-08-27 |
Баксалта Инкорпорейтед |
Конъюгаты белков свертывания крови
|
EP2588499B1
(de)
|
2010-06-30 |
2020-04-08 |
Novo Nordisk A/S |
Zur bindung des gewebefaktor-gerinnungsweg-inhibitors fähige antikörper
|
US8945897B2
(en)
|
2010-07-26 |
2015-02-03 |
Baxter International Inc. |
Materials and methods for conjugating a water soluble fatty acid derivative to a protein
|
RU2013142015A
(ru)
|
2011-03-02 |
2015-04-10 |
Ново Нордиск А/С |
Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов
|
ES2724778T3
(es)
|
2011-06-10 |
2019-09-16 |
Bioverativ Therapeutics Inc |
Compuestos procoagulantes y procedimientos de uso de los mismos
|
EP2554161A1
(de)
|
2011-08-02 |
2013-02-06 |
LFB Biotechnologies |
Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
|
CN104717973A
(zh)
|
2012-10-10 |
2015-06-17 |
诺和诺德保健Ag(股份有限公司) |
因子vii多肽的液体药物组合物
|
CN104661685A
(zh)
|
2012-10-15 |
2015-05-27 |
诺和诺德保健Ag(股份有限公司) |
因子vii缀合物
|
ES2856968T3
(es)
|
2016-01-15 |
2021-09-28 |
Rigshospitalet |
Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
|
CN114728044A
(zh)
|
2019-08-15 |
2022-07-08 |
介控生化科技公司 |
用于皮下施用和按需求治疗的经修饰的因子vii多肽
|